Clinical trial
Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of…
NCT00499109 · H. Lee Moffitt Cancer Center and Research Institute, Other · Completed
Key facts
| NCT number | NCT00499109 |
|---|---|
| Title | Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC |
| Official title | Randomized Phase III Multicenter Trial of RRM1 & ERCC1 Directed Customized Chemotherapy Versus Standard of Care for 1st Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Vinorelbine, Carboplatin, Gemcitabine |
| Enrollment | 275 |
| Start date | May 1, 2007 |
| Primary completion | Apr 1, 2013 |
| Completion | Nov 1, 2013 |
| First posted | Jul 11, 2007 |
| Last update posted | Jul 9, 2014 |
| Countries | Germany, Puerto Rico, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: